Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

All potential acute ischemic stroke patients meeting criteria for the use of IV tPA should be offered treatment. The facts are clear, and all that remains is further provider and patient education.

Intravenous delivered tPA is approved by the FDA for the treatment of acute ischemic stroke. The drug can make a big difference, but only if it is given within a specified time frame (up to four and a ...

The effects and risks of the use of intravenous thrombolysis between 4.5 and 24 hours after the onset of a posterior circulation ischemic stroke are not well studied. In a trial conducted in China ...

A new stroke thrombolytic — tenecteplase — marketed as TNKase — has received FDA approval, marking the first such advancement in nearly 30 years. Unlike alteplase (tPA), which requires a lengthy ...

You may be familiar with the common signs and symptoms of a stroke: loss of vision, drooping face, weak limbs, and slurred ...

No significant difference seen in terms of effectiveness or safety outcomes, including functional independence at discharge ...

In the US, the rate of ischemic stroke among adults aged 20 to 44 surged from 17 per 100,000 adults in 1993 to 28 per 100,000 in 2015. The risk of stroke death among young adults is also on the rise.

Sometimes treatment for an ischemic stroke is aimed at clearing the blockage. In select cases, this includes the use of intravenous (IV) tissue plasminogen activator, or tPA. This drug is most ...